Loading…
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $110M | $-136M | $-153M | $-163M | 145.5% | 21.4% | 21.0% |
| 2024 | $90M | $-110M | $-127M | $-97M | 1441.3% | 9.3% | 24.1% |
| 2023 | $83M | $-82M | $-102M | $-77M | 156.8% | 28.5% | -6.9% |
| 2022 | $64M | $-98M | $-110M | $-88M | 122.9% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 64.36 | 82.71 | 90.40 | 109.79 |
| Operating Revenue | - | 64.36 | 82.71 | 90.40 | 109.79 |
| Cost Of Revenue | - | 7.65 | 9.36 | 8.88 | 12.45 |
| Gross Profit | - | 56.70 | 73.35 | 81.52 | 97.34 |
| Operating Expense | - | 135.74 | 138.89 | 178.30 | 222.20 |
| Research And Development | - | 52.91 | 45.61 | 57.14 | 67.11 |
| Selling General And Administration | - | 82.84 | 93.27 | 121.15 | 155.10 |
| Total Expenses | - | 143.40 | 148.25 | 187.18 | 234.65 |
| Operating Income | - | -79.04 | -65.54 | -96.78 | -124.86 |
| Total Operating Income As Reported | - | -79.04 | -65.54 | -96.78 | -124.86 |
| EBITDA | - | -97.77 | -81.90 | -110.34 | -135.66 |
| Normalized EBITDA | - | -97.77 | -81.90 | -110.34 | -135.66 |
| EBIT | - | -99.59 | -83.61 | -111.52 | -138.07 |
| Interest Income | - | 0.94 | 2.64 | 8.90 | 5.96 |
| Interest Expense | - | 8.44 | 14.72 | 12.52 | 15.34 |
| Net Interest Income | - | -29.06 | -33.63 | -27.03 | -27.88 |
| Other Non Operating Income Expenses | - | 0.07 | 0.84 | -0.23 | -0.67 |
| Other Income Expense | - | 0.07 | 0.84 | -0.23 | -0.67 |
| Interest Income Non Operating | - | 0.94 | 2.64 | 8.90 | 5.96 |
| Interest Expense Non Operating | - | 8.44 | 14.72 | 12.52 | 15.34 |
| Net Non Operating Interest Income Expense | - | -29.06 | -33.63 | -27.03 | -27.88 |
| Pretax Income | - | -108.03 | -98.32 | -124.04 | -153.42 |
| Tax Provision | - | 1.76 | 3.92 | 2.83 | 0.08 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -109.78 | -102.24 | -126.87 | -153.49 |
| Net Income From Continuing And Discontinued Operation | - | -109.78 | -102.24 | -126.87 | -153.49 |
| Net Income From Continuing Operation Net Minority Interest | - | -109.78 | -102.24 | -126.87 | -153.49 |
| Net Income | - | -109.78 | -102.24 | -126.87 | -153.49 |
| Net Income Common Stockholders | - | -109.78 | -102.24 | -126.87 | -153.49 |
| Net Income Including Noncontrolling Interests | - | -109.78 | -102.24 | -126.87 | -153.49 |
| Normalized Income | - | -109.78 | -102.24 | -126.87 | -153.49 |
| Diluted NI Availto Com Stockholders | - | -109.78 | -102.24 | -126.87 | -153.49 |
| Basic Average Shares | - | 22.81 | 28.83 | 42.88 | 48.12 |
| Diluted Average Shares | - | 22.81 | 28.83 | 42.88 | 48.12 |
| Reconciled Depreciation | - | 1.82 | 1.70 | 1.19 | 2.41 |
| Reconciled Cost Of Revenue | - | 7.65 | 9.36 | 8.88 | 12.45 |
| Total Unusual Items | -17.29 | -21.56 | -21.55 | -23.41 | - |
| Total Unusual Items Excluding Goodwill | -17.29 | -21.56 | -21.55 | -23.41 | - |
| Gain On Sale Of Security | -17.29 | -21.56 | -21.55 | -23.41 | - |
| Total Other Finance Cost | - | 21.56 | 21.55 | 23.41 | 18.50 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| UroGen Pharma Ltd.this co. | URGN | $1.3B | -8.76 | -12.75 | 145.5% | -10.04 |
| MapLight Therapeutics, Inc. | MPLT | $1.4B | - | 2.98 | -35.2% | - |
| Butterfly Network, Inc. | BFLY | $1.4B | - | 6.93 | -39.3% | - |
| Bicara Therapeutics Inc. | BCAX | $1.3B | -9.72 | 3.34 | -34.4% | -8.01 |
| Inhibrx Biosciences, Inc. | INBX | $1.3B |
| - |
| - |
| - |
| - |
| - |
| -9.56 |
| 167.49 |
| -1752.2% |
| -10.54 |
| Ardelyx, Inc. | ARDX | $1.3B | -21.66 | 7.99 | -36.9% | -50.52 |
| Tandem Diabetes Care, Inc. | TNDM | $1.3B | -6.51 | 8.59 | -131.9% | -9.55 |
| AdaptHealth Corp. | AHCO | $1.3B | -18.70 | 0.87 | -4.7% | 6.60 |
| BioLife Solutions, Inc. | BLFS | $1.3B | -288.04 | 3.56 | -1.2% | -109.81 |
| Peer Median | - | -14.21 | 5.24 | -36.0% | -10.05 | |